
Conference Coverage
Latest News

NeurologyLive® Friday 5 — August 7, 2026

Bezisterim Shows Improvements in Motor, Nonmotor Symptoms in Phase 2 SUNRISE-PD Trial

Pediatrics to Adulthood: What the LGS Care Transition is Still Getting Wrong

Episode 172: Spinal Muscular Atrophy Awareness Month: Why Multidisciplinary Care Matters

Favorable Phase 1 Data for Orexin-2 Agonist BP-205, Broader Pipeline Progress Headline Harmony's Q2 Update

Shorts










Videos
Podcasts
Continuing Medical Education
All News

The FDA has granted 510(k) clearance to VoxNeuro's Cognitive Function Neuroimaging software, an EEG/ERP-based tool designed to give clinicians an objective, adjunctive measure of cognitive function.

Neurologist Takaomi Saido, PhD, discusses decades of research into the neprilysin-donanemab and amyloid-beta–tau axes in Alzheimer disease, highlighting potential mechanisms underlying the transition from amyloid to tau pathology and opportunities to develop earlier, more targeted disease-modifying therapies.

Six FDA PDUFA decisions this fall could reshape care in Alzheimer disease, DMD, Sanfilippo syndrome, Alexander disease, and SMA, here's what clinicians need to know about the data behind each.

The FDA has approved oveporexton, marketed as Orzeyful, as the first therapy to directly restore orexin signaling and address the full symptom range of narcolepsy type 1.

In recognition of SMA Awareness Month, held annually throughout August, NeurologyLive® summarized the latest literature on the multidisciplinary care approach for patients living with spinal muscular atrophy.

Elizabeth Ferluga, MD, and Kristen Fortino discuss a newly launched virtual care program, the barriers facing patients with ataxia, and the potential for remote access to specialized care to improve diagnosis, treatment, and clinical trial connectivity.

The associate professor at the University of Michigan covered the 2026 Peripheral Nerve Society Annual Meeting, highlighting emerging themes in GBS, SMA, TTR neuropathy, RFC1, and what is still keeping the field up at night.

The FDA has granted Regenerative Medicine Advanced Therapy designation to sasineprocel, an autologous cell therapy for Parkinson disease, based on early data from the ongoing ASPIRO trial.

A recently published study showed that 4 weeks of high-dose oral N-acetyl cysteine significantly reduced serum GFAP levels in adults with progressive multiple sclerosis compared with placebo.

Real-world data from a London MS pregnancy clinic showed persistent B-cell depletion and favorable postpartum disease outcomes in women who discontinued ofatumumab upon confirmed pregnancy.

The FDA has accepted Saol Therapeutics' resubmitted NDA for SL1009 in pyruvate dehydrogenase complex deficiency, setting a new PDUFA target action date of December 30, 2026.

Catch up on any of the neurology headlines you may have missed in July 2026, compiled into 1 place by the NeurologyLive® team.

Cleveland Clinic experts Trishul Kapoor, MD, and Osama Kashlan, MD, discussed how advanced diagnostics, basivertebral nerve ablation, endoscopic surgery, and neuromodulation unite to ease chronic back pain.

Here's some of what is coming soon to NeurologyLive® this week.

A new cross-sectional study found that professional identity partially explains the connection between burnout and missed nursing care among neuro-oncology nurses in China, with psychological capital buffering both pathways.
































